Company / Cash & Equivalents
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Cash & Equivalents History
FY2015-FY2015 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$44.4K
FY2015
5-year range
$44.4K / $44.4K
FY2015-FY2015
Trend
-
vs FY2014
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$44,411 in FY2015.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Company context
Key Data Points
- Altman Z-Score -11.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2015 | $44.4K | - |
| FY2013 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2015 · SEC 10-K · Updated Jun 24, 2026